Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine versus fludarabine + cytarabine in elderly patients with newly diagnosed acute myeloid leukemia
2014-000319-15Phase 3Completed
- Sponsor
- Fundación PETHEMA
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azacitidine, fludarabine and cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by Fundación PETHEMA. Primary endpoint: Overall survival at 1 year. Started Jun 2014; status: completed.
02
Drugs
azacitidinefludarabinecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2014-000319-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000319-15.